Ticker brief
MPLT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
5
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-01 · now +0.10 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 2 | +0.08 |
| @Quantumup1 | C | -1.95 | 2 | +0.45 |
| @BiopharmIQ | B | · | 2 | +0.10 |
| @BioStocks | C | -0.39 | 1 | -0.60 |
| @OpenOutcrier | C | · | 1 | -0.60 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @BiopharmIQ | +0.10 | Biotech catalyst watchlist with 52 Q3 readouts and named trial dates. | · | tweet ↗ |
| 2026-06-28 | @BiopharmIQ | +0.10 | Biotech catalyst watchlist with Phase 2/3 readouts in Q3 2026, capped to first six tickers. | · | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.55 | Raymond James initiated MPLT at Strong Buy with $46 target. | · | tweet ↗ |
| 2026-06-23 | @Quantumup1 | +0.35 | Craig-Hallum cuts PT while H.C. Wainwright reiterates Buy $45 after mixed Phase 2 results. | · | tweet ↗ |
| 2026-06-23 | @OzmosiHealth | +0.15 | MapLight presented Phase 2 autism spectrum disorder results on 2026-06-22. | · | tweet ↗ |
| 2026-06-22 | @OzmosiHealth | +0.00 | MapLight announced topline Phase 2 IRIS study results; outcome not stated. | · | tweet ↗ |
| 2026-06-22 | @OpenOutcrier | -0.60 | MapLight autism drug trial misses primary endpoint. | · | tweet ↗ |
| 2026-06-22 | @BioStocks | -0.60 | MPLT Phase 2 trial did not meet primary endpoint in ASD social communication deficits. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.